Please assess the completion status of the following clinical trial:

Trial Title: Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Addition eligibility criteria based on tumor type apply~Inclusion Criteria:~* Ability to provide written informed consent in accordance with federal, local, and institutional guidelines~* Histological or cytological diagnosis of metastatic cancer or locally advanced cancer that is not amenable to local therapy~* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1~* Life Expectancy of at least 3 months~* Adequate hepatic, renal, cardiac, and hematologic function~* Measurable disease by Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 criteria~* Resolution of treatment-related toxicities except alopecia~Exclusion Criteria:~* Unable to receive oral medications~* Unable to receive oral or intravenous (IV) hydration~* Intolerance to prior anti-PD-1/PD-L1 therapy~* Prior severe hypersensitivity reaction to another monoclonal antibody (mAb)~* Any other current or previous malignancy within 3 years except protocol allowed malignancies~* Chemotherapy, TKI therapy, radiation therapy or hormonal therapy within 2 weeks~* Immunotherapy or biological therapy, or investigational agent within 3 weeks (Note: Some cohort exceptions allow anti-PD-1 therapy)~* Active known or suspected exclusionary autoimmune disease~* Any condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalent) or other systemic immunosuppressive medications within 2 weeks~* History of known risks factors for bowel perforation~* Symptomatic ascites or pleural effusion~* Major surgery within 28 days before Cycle 1 Day 1~* Active infection requiring parenteral antibiotics, antivirals, or antifungals within 2 weeks prior to first dose of study drug~* Patients who have human immunodeficiency virus (HIV), Hepatitis B or C~* Conditions that could interfere with treatment or protocol-related procedures~* Active and/or untreated central nervous system (CNS) disease or non-stable brain metastases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telaglenastat 600 mg + Standard Dose Nivolumab (Type: EXPERIMENTAL): Telaglenastat 600 mg in combination with standard dose nivolumab in participants with advanced/metastatic clear cell renal cell carcinoma (ccRCC), melanoma, and non-small cell lung cancer (NSCLC).
- Telaglenastat 800 mg + Standard Dose Nivolumab: ccRCC Naïve to Checkpoint Inhibitors (Type: EXPERIMENTAL): Telaglenastat 800 mg/standard dose nivolumab combination in participants with advanced/metastatic ccRCC who have previously received at least one tyrosine kinase inhibitor (TKI) but are treatment naïve to checkpoint modulators programmed death-1/programmed death ligand-1 (PD-1/PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), or any other agent that specifically targets a T-cell checkpoint or co-stimulation pathway.
- Telaglenastat 800 mg + Standard Dose Nivolumab: ccRCC Recently Treated With Nivolumab (Type: EXPERIMENTAL): Telaglenastat 800 mg/standard dose nivolumab combination in participants with advanced/metastatic ccRCC who received nivolumab in most recent treatment line that had documented radiological disease progression OR are currently receiving nivolumab with stable disease for at least 24 weeks.
- Telaglenastat 800 mg + Standard Dose Nivolumab: ccRCC With Prior PD-1 Therapy (Type: EXPERIMENTAL): Telaglenastat 800 mg/standard dose nivolumab combination in participants with advanced/metastatic ccRCC that had documented radiological disease progression while receiving an anti-PD-1/PD-L1 therapy in any prior line of therapy.
- Telaglenastat 800 mg + Standard Dose Nivolumab: Melanoma With Prior PD-1 Therapy (Type: EXPERIMENTAL): Telaglenastat 800 mg/standard dose nivolumab combination in participants with unresectable or metastatic melanoma that had documented radiological disease progression while receiving an anti-PD-1 therapy in their most recent line of therapy.
- Telaglenastat 800 mg + Standard Dose Nivolumab: NSCLC With Prior PD-1 Therapy (Type: EXPERIMENTAL): Telaglenastat 800 mg/standard dose nivolumab combination in participants with NSCLC that does not harbor an activating mutation in the epidermal growth factor receptor (EGFR) oncogene and who received nivolumab in most recent treatment line and had documented radiological disease progression OR are currently receiving nivolumab with Stable Disease for at least 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy